Tissue engineering technologies and cell therapies are providing physicians with options to treat diseases by creating new tissues that can replace diseased or traumatized tissues. And the advances are not in laboratory but in hospitals in treatment of large numbers of patients. The global market for technologies in tissue engineering and cell therapy is already at $6.9 billion, but will grow to $32 billion over the next ten years as a result of the clinical successes possible with these products.
In terms of clinical specialties, the segment expected to experience the most rapid growth is organ transplantation and related technologies. Over the 2009–2018 period, this segment is expected to grow by roughly 46%. This unusually explosive growth is expected due to: (1) the large demand for effective therapies for chronic diseases as those involving the pancreas (diabetes), liver and heart; and (2) development of regenerative technologies related to therapies for these diseases is among the most advanced among all gene and cell therapy-based developments.
[Image at right from "Visualization of Tissue Engineering", National Institute of Standards and Technology.]
The segment expected to grow the second most rapidly from 2009 to 2018 comprises therapies for dental decay and disease. The growth rate expected here is roughly 21%. Several technologies in this segment, such as bone and tissue grafts, are already being marketed rather but rather than hitting a plateau, growth in this segment expected to be sustained by an aging population that will result in an increase in the numbers of people who can benefit from these therapies.
Regenerative medicine with applications in cardiology and vascular medicine is also expected to rank among the three fastest growing segments in this area of medicine. This growth, to equal roughly 20% from 2009 to 2018, is expected to result from commercialization of several innovative therapies that are expected to reach regulatory approval status.
Current treatments using tissue engineering and cell therapy span cardiology, neurology, orthopedics, urology, skin & plastic surgery, dental/oral surgery, organ replacement, ophthalmology, general/abdominal/gynecologic/other surgery, cancer and cord blood & cell banking.
Drawn from the data in "Tissue Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, Worldwide, 2009-2018", Report #S520, published by MedMarket Diligence.
If you enjoyed this article, please consider sharing it!
-
Anonymous
-
tomgarrand
